englishEn

Production

Business advantages

Among Hemofarm’s most important business advantages are: a professional staff motivated towards achieving top results; technological completeness; implementation of the latest pharmaceutical standards; an extensive and up-to-date portfolio; certified quality management, as well as high quality and prestigious research and development projects.

Hemofarm group - Plants

Vršac

Central manufacturing complex: involves four manufacturing plants and an automated high-bay warehouse - manufacture of solid dosage medicinal forms, sterile products, infusion solutions, and injectables.

Podgorica

Manufacture of infusion solutions, ophthalmologist products, and cephalosporin antibiotics.

Šabac

Manufacture of solid dosage medicinal forms, liquid and semi-liquid products.

Banja Luka

Manufacture of solid dosage medicinal forms.

Dubovac

Manufacture of antibiotics.

In 2014, Hemofarm produced 4.4 billion product units, a 13% increase in relation to the previous year. Out of the total number of the units manufactured in 2014, 3.9 billion, or about 90%, were solid dosage forms – tablets, film-coated tablets, and capsules.

All the manufacturing plants of the Hemofarm Group have contributed to this result. These plants have been increasing production for the demanding EU markets, and at the level of the STADA Group, they are the largest producers and the backbone of further development.

Increase in production volume

In addition to the increase in production volume in 2014, further increase of assortment was recorded, too. The portfolio included 1.974 different products, an increase of 15% in relation to the previous year. This is the widest recorded assortment of production in the history of the company so far. Hemofarm has been continuously enhancing its portfolio, launching new products every year with the primary aim of meeting the needs of patients and consumers. In this way, Hemofarm contributes to improving the quality and stability of people’s lives, and better supply levels of the local pharmaceutical market.

Focus

Production is focused on Rx and OTC products within the most important pharmacotherapeutic groups, such as for cardiovascular diseases, antibiotics or neuropsychiatric medicines.

Sales in EU

The production of a considerable number of products for the STADA Group intended for sale in EU countries is evidence of our modern concept of pharmaceutical industry, top-class technological equipment and staff competence.

2010 - 2014 Production

in millions of packs

More than 202 million packs produced in 2014 – the largest volume in the history of the company.

With a manufacturing capacity of 46 million bottles per annum, Hemofarm is among the 5 largest European manufacturers of infusion solutions.